TY - JOUR
T1 - Sick leave duration as a potential marker of functionality and disease severity in depression
AU - Volz, Hans Peter
AU - Bartečků, Elis
AU - Bartova, Lucie
AU - Bessa, João
AU - De Berardis, Domenico
AU - Dragasek, Jozef
AU - Kozhuharov, Hristo
AU - Ladea, Maria
AU - Lazáry, Judit
AU - Roca, Miquel
AU - Usov, Grigory
AU - Wichniak, Adam
AU - Godman, Brian
AU - Kasper, Siegfried
N1 - Funding Information:
HPV has served as a consultant or on advisory boards for Astra/Zeneca, Eli Lilly, Lundbeck, Pfizer, Schwabe, Janssen, Otsuka, Angelini and Sage and has served on speakers’ bureaus for Astra/Zeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Bayer, Recordati and Neuraxpharm. EB has received honoraria from Angelini. LB has received travel grants and consultant/speaker honoraria from AOP Orphan, Medizin Medien Austria, Vertretungsnetz, Schwabe Austria, Janssen and Angelini. JD is a consultant to Angelini. HK reports compensation by Angelini and Janssen for the delivery of lectures. ML has served as a consultant on advisory boards for Angelini and has received consulting and lecturing fees from Angelini, Gedeon Richter, Janssen and Servier in the last year. JL reports participating in an advisory role for Angelini. MR reports receiving grants from the European Union, the Spanish Ministry of Economy and Competitiveness and research funding or fees from Angelini, Janssen and Lundbeck. GU reports serving on advisory boards or providing consultancy for Abbott and Angelini and has received speaker’s fees/honoraria from Angelini, Servier, Lundbeck, Abbott, Pfizer/Viatris and Krka. He has also received travel support from Servier, Lundbeck, Abbott and Pfizer. SK has received grants/research support, consulting fees and/or honoraria within the last three years, including grant/research support from Lundbeck. He has also served as a consultant or on advisory boards for Celegne, IQVIA, Janssen, Lundbeck, Mundipharma, Recordati, Takeda and Schwabe, and on speaker’s bureaus for Angelini, Aspen Farmaceutica S.A., Janssen, Krka, Lundbeck, Medichem Pharmaceuticals Inc., Neuraxpharma, OM Pharma, Pierre Fabre, Sanofi, Servier, Schwabe, Sun Pharma. All authors received honoraria from Angelini for their consultant/advisory role in the advisory board meeting that led to the development of this manuscript. Acknowledgements
Funding Information:
The virtual expert meeting and preparation of this manuscript were funded by Angelini Pharma. Editorial assistance was provided by John Scopes of mX m Medical Communications.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression. Key points Depression in the working population and depression-related sick leave have a profound economic impact on society Depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions A wide variety of pharmacological and non-pharmacological treatments and work-based interventions have been shown to be effective in reducing depression-related sick leave duration and/or facilitating return to work In terms of pharmacological intervention, recent real-world evidence has shown that patients treated with antidepressant monotherapy are able to recover their working life faster than those treated with combination therapy Although depression-related sick leave duration has been shown to correlate with severity of depressive symptoms, it is not a viable outcome measure of depression severity on its own, but could be used as secondary outcome alongside more formal clinician- and patient-rated severity measures Depression-related sick leave duration may, however, represent a viable outcome for measuring functionality in depression.
AB - Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression. Key points Depression in the working population and depression-related sick leave have a profound economic impact on society Depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions A wide variety of pharmacological and non-pharmacological treatments and work-based interventions have been shown to be effective in reducing depression-related sick leave duration and/or facilitating return to work In terms of pharmacological intervention, recent real-world evidence has shown that patients treated with antidepressant monotherapy are able to recover their working life faster than those treated with combination therapy Although depression-related sick leave duration has been shown to correlate with severity of depressive symptoms, it is not a viable outcome measure of depression severity on its own, but could be used as secondary outcome alongside more formal clinician- and patient-rated severity measures Depression-related sick leave duration may, however, represent a viable outcome for measuring functionality in depression.
KW - Absenteeism
KW - depression
KW - functionality
KW - major depressive disorder
KW - return to work
KW - sick leave
UR - http://www.scopus.com/inward/record.url?scp=85129143834&partnerID=8YFLogxK
U2 - 10.1080/13651501.2022.2054350
DO - 10.1080/13651501.2022.2054350
M3 - Review article
C2 - 35373692
AN - SCOPUS:85129143834
SN - 1365-1501
VL - 26
SP - 406
EP - 416
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
IS - 4
ER -